Is it True That Fenbendazole Cancer?

Fenbendazole cancer dosage - Recently, several cancer patients were hospitalized at the university hospital due to side effects after taking medicines against worms and one of them died, amid growing concern about cancer patients rushing to take medications anthelmintics to cure their diseases.

Defying warnings from the Korean Medical Association and the Ministry of Food Safety and Medicine against the use of medications for unexpected side effects, radiology oncologist Kim Ja-young said on his YouTube channel that it was safe to take fenbendazole. His accusations immediately invited criticism from the medical community.

According to Kim, fenbendazole has been safe for 40 years, and the absorption rate of human drugs is very low at 20%, making it difficult to display toxicity. In addition, this substance is poisonous to low-level organisms, such as parasites, and less toxic to high-level organisms such as humans and mammals, he said. Even if a patient takes fenbendazole for three days in a row, resting for four days will release most of the medicinal ingredients, Kim says.

If a patient takes fenbendazole liquid 2,000 mg at a time, it has no acute side effects and the patient can buy medicines for human earthworms with mebendazole and albendazole at the pharmacy.

Fenbendazole cancer dosage - Kim explains how to catch dog worms in detail. For a patient with metastatic cancer who is developing rapidly and many, he recommends taking 222mg of fenbendazole four times a day for three weeks, taking 222mg once or twice a day after the third week and resting for four days. It is safe to use high doses of fenbendazole, because in the past patients used high doses of mebendazole, up to 2,000 to 3,000 mg for more than three weeks, when parasites were found in the brain, Kim continued.

He also detailed the amount of fenbendazole to be taken and the treatment schedule for those who benefit from the medication. To increase the absorption rate, the patient should take medication immediately after eating or taking worm pills with olive oil from 60 to 100cc so that bile can be removed.

How is Fenbendazole Based on Research?

Studies conducted by others have shown that fenbendazole can alter the growth of various tumors in mice. Therefore, previous studies in our laboratory examined the effects of a standard commercial therapeutic diet, commonly used to prevent or treat worms in rat colonies, on the growth and radiation response of EMT6 tumors, to verify whether the use of the diet would harm us. experimental cancer therapy studies. We do not see evidence that the therapeutic diet alters the growth or radiation response of the EMT6 tumor.

Fenbendazole cancer dosage - During the project, limited cell growth studies were conducted to verify whether THE 6S6 culture was sensitive to this medication when administered in continuous incubation. Fenbendazole did not produce significant changes in the growth of EMT6 cells in vitro at concentrations of 0.11 and 0.33 μM but produced noticeable growth inhibition at doses of 1 and 3 μM.

At this higher dose, we also observed a change in the appearance of the culture: the cells in the culture to be treated are more rounded than the control cells and are less firmly attached to the growth surface, according to the expected effect of the impaired balance of tubulin microtubules. Limited data available on fenbendazole pharmacokinetics in rats suggest that the experimental diet used in our previous study produces a maximum tissue level of 0.1 μM or less. Thus, our cell culture data are in accordance with data from tumors of rats fed fenbendazole containing anthelmintic.

However, in vitro data also show that higher concentrations of drugs have a very significant effect on the growth of these tumor cells in culture.

The research presented here expands previous research to examine the effect of higher doses of fenbendazole on the viability of EMT6 cells in vitro, using rigorous colony formation tests to measure cell survival. These data indicate that 24-hour incubation with high doses of fenbendazole reduces the clonogenicity of EMT6 cells, in addition to reducing the number of cells in culture. Fenbendazole, therefore, has a cytotoxic and cytostatic effect on these tumor cells when used in high concentrations and with long incubations.

The cytotoxicity of 2-hour treatment with fenbendazole increases when tumor cells are treated under severe hypoxia. Fenbendazole cancer dosage - However, the preferential toxicity of fenbendazole to hypoxic cells is relatively simple, and small differences indicate that fenbendazole may not have therapeutic uses as a hypoxic selective anticancer drug.

In conclusion, despite the overlapping mechanism of action of fenbendazole with that of selective nitro-heterocyclic cytotoxins and vinca radiosensitizers, taxanes and alkaloids, our study does not provide evidence that fenbendazole warrants further testing as a potential agent for use in cancer therapy.

However, it is very possible that the related compound may be a valuable anticancer drug. Given the current interest of the U.S. Food and Drug Administration is examining the possibility of 'redirecting' previously approved drugs, with clear characteristics and good toxicological data for new uses, it may be necessary to explore other anti-helminths developed in the past to verify whether this class of agents is included compounds that may be valuable in cancer therapy, either because of a significant differential effect on hypoxic cells or by their effects on the balance of tubulin microtubules.

It is likely that agents that are not being pursued use as antiparasitic, agents due to increased absorption of the intestine (and therefore greater toxicity in the host), may provide new anticancer agents or valuable new compounds in the development of new antineoplastic drugs. because of a significant differential effect on hypoxic cells or its effect on the balance of tubulin microtubules.